Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Rare Disease | 41.7 | | | | | | | |
| Generics, Established Brands and Other | 274.7 | 216.1 | 208.5 | | | | | |
| Total revenues | 316.4 | 216.1 | 208.5 | 206.5 | 201.6 | 176.8 | 128.6 | 76.3 |
| Revenue growth [+] | 46.4% | 3.7% | 0.9% | 2.5% | 14.0% | 37.5% | 68.5% | 36.4% |
| Generics, Established Brands and Other | 27.1% | 3.7% | | | | | | |
| Cost of goods sold | 142.5 | 101.9 | 98.4 | 69.9 | 73.0 | 79.0 | 48.8 | 12.7 |
| Gross profit | 173.8 | 114.2 | 110.1 | 136.7 | 128.6 | 97.8 | 79.8 | 63.6 |
| Gross margin | 54.9% | 52.9% | 52.8% | 66.2% | 63.8% | 55.3% | 62.1% | 83.4% |
| Selling, general and administrative | 124.0 | 84.3 | 65.0 | 55.8 | 44.1 | 31.6 | 27.8 | 21.2 |
| Research and development | 22.3 | 11.4 | 16.0 | 19.8 | 15.4 | 9.1 | 2.9 | 2.9 |
| Other operating expenses | -7.5 | -0.7 | | | | | | |
| EBITDA [+] | 37.7 | 19.3 | 29.1 | 61.0 | 69.1 | 57.2 | 49.1 | 39.6 |
| EBITDA growth | 95.4% | -33.7% | -52.4% | -11.7% | 20.9% | 16.4% | 24.0% | 65.8% |
| EBITDA margin | 11.9% | 8.9% | 13.9% | 29.6% | 34.3% | 32.3% | 38.2% | 51.9% |
| Depreciation | 10.2 | 5.5 | 4.7 | 4.4 | 2.0 | 1.2 | 0.9 | 0.7 |
| EBITA | 27.5 | 13.8 | 24.3 | 56.6 | 67.1 | 55.9 | 48.2 | 38.9 |
| EBITA margin | 8.7% | 6.4% | 11.7% | 27.4% | 33.3% | 31.6% | 37.4% | 51.0% |
| Amortization of intangibles | 49.5 | 41.8 | 39.9 | 40.2 | 31.7 | 26.7 | 21.4 | 6.2 |
| EBIT [+] | -22.0 | -28.0 | -15.6 | 16.4 | 35.4 | 29.2 | 26.8 | 32.7 |
| EBIT growth | -21.4% | 79.6% | -194.8% | -53.5% | 21.0% | 9.2% | -18.2% | 63.5% |
| EBIT margin | -6.9% | -12.9% | -7.5% | 8.0% | 17.5% | 16.5% | 20.8% | 42.8% |
| Non-recurring items [+] | 13.3 | 11.8 | 0.4 | 0.1 | | 0.9 | 6.7 | |
| Asset impairment | 0.1 | 2.4 | 0.4 | 0.1 | | 0.9 | 6.7 | |
| Legal settlement | | 8.8 | | | | | | |
| Loss on contingent liability | 3.8 | 0.5 | | | | | | |
| Interest expense | 28.1 | 11.9 | 9.5 | 13.0 | 14.8 | 12.0 | 11.3 | 11.0 |
| Interest expense | 28.1 | 11.9 | 9.5 | 13.0 | 14.8 | 12.0 | 11.3 | 11.0 |
| Other income (expense), net [+] | 0.7 | -4.3 | -0.5 | -0.2 | -0.6 | 0.1 | -0.1 | 0.0 |
| Other | 0.7 | -4.3 | -0.5 | -0.2 | -0.6 | 0.1 | -0.1 | 0.0 |
| Pre-tax income | -62.7 | -56.1 | -26.0 | 3.2 | 20.1 | 16.3 | 8.7 | 21.7 |
| Income taxes | -14.8 | -13.5 | -3.4 | -2.9 | 4.6 | 17.4 | 4.7 | 6.4 |
| Tax rate | 23.6% | 24.0% | 13.1% | | 22.7% | 106.6% | 54.7% | 29.3% |
| Net income | -49.5 | -42.8 | -22.5 | 6.1 | 15.5 | -1.1 | 3.9 | 15.4 |
| Net margin | -15.7% | -19.8% | -10.8% | 3.0% | 7.7% | -0.6% | 3.1% | 20.1% |
| |
| Basic EPS [+] | ($3.05) | ($3.40) | ($1.88) | $0.51 | $1.33 | ($0.09) | $0.34 | $1.35 |
| Growth | -10.4% | 80.3% | -466.2% | -61.2% | -1523.9% | -127.1% | -74.6% | -48.5% |
| Diluted EPS [+] | ($3.05) | ($3.40) | ($1.88) | $0.51 | $1.32 | ($0.09) | $0.34 | $1.33 |
| Growth | -10.4% | 80.3% | -472.4% | -61.5% | -1512.4% | -127.4% | -74.4% | -48.8% |
| |
| Dividends per share [+] | $0.10 | $0.02 | | | | | | |
| Growth | 562.5% | | | | | | | |
| |
| Shares outstanding (basic) [+] | 16.3 | 12.6 | 12.0 | 11.8 | 11.7 | 11.5 | 11.4 | 11.4 |
| Growth | 29.1% | 5.3% | 1.0% | 1.4% | 1.1% | 0.9% | 0.7% | 3.9% |
| Shares outstanding (diluted) [+] | 16.3 | 12.6 | 12.0 | 12.0 | 11.8 | 11.5 | 11.6 | 11.6 |
| Growth | 29.1% | 5.3% | -0.6% | 2.3% | 1.9% | -0.2% | 0.1% | 4.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|